Modeling proteasome dynamics in Parkinson's disease

In Parkinson's disease (PD), there is evidence that alpha-synuclein (alphaSN) aggregation is coupled to dysfunctional or overburdened protein quality control systems, in particular the ubiquitin-proteasome system. Here, we develop a simple dynamical model for the on-going conflict between alphaSN aggregation and the maintenance of a functional proteasome in the healthy cell, based on the premise that proteasomal activity can be titrated out by mature alphaSN fibrils and their protofilament precursors. In the presence of excess proteasomes the cell easily maintains homeostasis. However, when the ratio between the available proteasome and the alphaSN protofilaments is reduced below a threshold level, we predict a collapse of homeostasis and onset of oscillations in the proteasome concentration. Depleted proteasome opens for accumulation of oligomers. Our analysis suggests that the onset of PD is associated with a proteasome population that becomes occupied in periodic degradation of aggregates. This behavior is found to be the general state of a proteasome/chaperone system under pressure, and suggests new interpretations of other diseases where protein aggregation could stress elements of the protein quality control system.

[1]  R. Sandri-Goldin,et al.  ICP27 Interacts with the C-Terminal Domain of RNA Polymerase II and Facilitates Its Recruitment to Herpes Simplex Virus 1 Transcription Sites, Where It Undergoes Proteasomal Degradation during Infection , 2006, Journal of Virology.

[2]  Y. Murakami,et al.  Hybrid Proteasomes , 2000, The Journal of Biological Chemistry.

[3]  Kim Sneppen,et al.  Quantifying the benefits of translation regulation in the unfolded protein response , 2004, Physical biology.

[4]  K. Davies,et al.  Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  M. Briand,et al.  Linkage between the proteasome pathway and neurodegenerative diseases and aging , 2004, Molecular Neurobiology.

[6]  K. Sneppen,et al.  Oscillations and temporal signalling in cells , 2007, Physical biology.

[7]  T. Reinheckel,et al.  Degradation of oxidized proteins in mammalian cells , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Shubo Han,et al.  The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.

[9]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[10]  Jean-Christophe Rochet,et al.  Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. , 2004, Journal of molecular neuroscience : MN.

[11]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[12]  Daniel Offen,et al.  Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage , 2006, Neuroscience Letters.

[13]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[14]  Min Zhu,et al.  Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.

[15]  Y. Imai,et al.  Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.

[16]  K. Sneppen,et al.  Theoretical Analysis of Epigenetic Cell Memory by Nucleosome Modification , 2007, Cell.

[17]  V. Uversky,et al.  Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .

[18]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[19]  N. Gonatas,et al.  Effect of ubiquitin expression on neuropathogenesis in a mouse model of familial amyotrophic lateral sclerosis , 2005, Neuropathology and applied neurobiology.

[20]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[21]  E. Stadtman,et al.  Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. , 1993, Annual review of biochemistry.

[22]  V. Subramaniam,et al.  NMR of α‐synuclein–polyamine complexes elucidates the mechanism and kinetics of induced aggregation , 2004, The EMBO journal.

[23]  T. Zglinicki,et al.  Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. , 2000, Free radical biology & medicine.

[24]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[25]  Theodore W Randolph,et al.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.

[26]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[27]  V. Uversky,et al.  Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .

[28]  K. Sneppen,et al.  Time delay as a key to apoptosis induction in the p53 network , 2002, cond-mat/0207236.

[29]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[30]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[31]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[32]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Tanaka,et al.  Half-life of proteasomes (multiprotease complexes) in rat liver. , 1989, Biochemical and biophysical research communications.

[34]  H. Pakkenberg,et al.  MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study. , 1999, Neurotoxicology and teratology.

[35]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[36]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[37]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[38]  K Sneppen,et al.  Thermodynamics of heat-shock response. , 1999, Physical review letters.

[39]  B. Friguet,et al.  Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[40]  C. Marsden,et al.  Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. , 1993, European journal of pharmacology.

[41]  Armin Giese,et al.  Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.

[42]  K Tanaka,et al.  Structure and functions of the 20S and 26S proteasomes. , 1996, Annual review of biochemistry.

[43]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[44]  V. Uversky,et al.  Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. , 2002, Biochemistry.

[45]  K. Chung,et al.  Dequalinium-induced Protofibril Formation of α-Synuclein* , 2006, Journal of Biological Chemistry.

[46]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[47]  A. Cuervo,et al.  Degradation of proteasomes by lysosomes in rat liver. , 1995, European journal of biochemistry.

[48]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[49]  V. Uversky,et al.  Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. , 2003, Biochemistry.

[50]  Kostas Vekrellis,et al.  Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.

[51]  Kim Sneppen,et al.  Ultrasensitive gene regulation by positive feedback loops in nucleosome modification , 2008, Molecular systems biology.

[52]  Jeff Kuret,et al.  Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.

[53]  C. Deocaris,et al.  Proteasomal Oscillation during Mild Heat Shock in Aging Human Skin Fibroblasts , 2006, Annals of the New York Academy of Sciences.

[54]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[55]  J. Paramio,et al.  Changes in proteasome localization during the cell cycle. , 1994, European journal of cell biology.

[56]  C. K. Lee,et al.  Gene expression profile of aging and its retardation by caloric restriction. , 1999, Science.

[57]  C. Dobson,et al.  Molecular determinants of the aggregation behavior of α‐ and β‐synuclein , 2008, Protein science : a publication of the Protein Society.

[58]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[59]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[60]  Hidefumi Ito,et al.  Immunocytochemical Co‐localization of the Proteasome in Ubiquitinated Structures in Neurodegenerative Diseases and the Elderly , 1997, Journal of neuropathology and experimental neurology.

[61]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[62]  L. Regan,et al.  A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. , 2003, Biophysical journal.

[63]  William E. Balch,et al.  An Adaptable Standard for Protein Export from the Endoplasmic Reticulum , 2007, Cell.

[64]  N. Chondrogianni,et al.  Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures , 2004, Biogerontology.

[65]  Sandeep Krishna,et al.  Oscillation patterns in negative feedback loops , 2006, Proceedings of the National Academy of Sciences.

[66]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .

[67]  Tobias Jung,et al.  Oxidized proteins: intracellular distribution and recognition by the proteasome. , 2007, Archives of biochemistry and biophysics.

[68]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[69]  J. Ferrell Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. , 2002, Current opinion in cell biology.

[70]  K. Sneppen,et al.  Minimal model of spiky oscillations in NF-κB signaling , 2006 .

[71]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[72]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[74]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[75]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[76]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[77]  B. Friguet,et al.  Inhibition of the multicatalytic proteinase (proteasome) by 4‐hydroxy‐2‐nonenal cross‐linked protein , 1997, FEBS letters.